Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
 

Research Phase

News Articles for Research Phase (20)
 
News Articles for Research Phase top ^
2013/6/3
Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO
Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO Canada NewsWire QUÉBEC CITY, June 3, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that final data for the Phase 1 portion of the ongoing Phase 1/2 trial with its lead oncology compound, zoptarelin doxorubicin (AEZS-108), demonstrated the compound's promising anti-tumor activity in heavily pre-treated men with castration- and taxane-resistant prostate cancer.
View more Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO analysis
Sign-up for Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO investment picks
2013/6/3
Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO
QUÉBEC CITY, June 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that final data for the Phase 1 portion of the ongoing Phase 1/2 trial with its lead oncology compound, zoptarelin doxorubicin (AEZS-108), demonstrated the compound's promising anti-tumor activity in heavily pre-treated men with castration- and taxane-resistant prostate cancer.
View more Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO analysis
Sign-up for Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO investment picks
2013/4/24
Chimerix Announces Final Study Design for Phase 3 SUPPRESS Trial of CMX001 for Prevention of CMV Infection
CMX001 demonstrated potential clinical utility in prevention of CMV infection in Phase 2 SUPPRESS trial anticipated to begin dosing mid-2013 with topline data expected in 2015 DURHAM, N.C., April 24, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the final study design for the Phase 3 SUPPRESS trial of CMX001 in the prevention of cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT). CMX001 is an investigational oral nucleotide analog lipid-conjugate that has shown broad-spectrum antiviral activity against double-stranded DNA (dsDNA) viruses including all of the herpesviruses, adenoviruses and polyomaviruses.
View more Chimerix Announces Final Study Design for Phase 3 SUPPRESS Trial of CMX001 for Prevention of CMV Infection analysis
Sign-up for Chimerix Announces Final Study Design for Phase 3 SUPPRESS Trial of CMX001 for Prevention of CMV Infection investment picks
2013/2/26
Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a global pivotal Phase 3 development program for fixed-dose combinations of VX-809 (lumacaftor) and ivacaftor in people with cystic fibrosis (CF) who have two copies (homozygous) of the F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene.
View more Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation analysis
Sign-up for Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation investment picks
2013/1/31
CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, announced that the Data Safety Monitoring Committee overseeing the Company’s global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) has recommended conducting the clinical trial through completion.
View more CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer analysis
Sign-up for CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer investment picks
2013/3/19
BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development
BMN-701 Meaningfully Improves Respiratory Endpoints Phase 2/3 Switch Study Expected to Begin by December 2013 SAN RAFAEL, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from POM-001, the Phase 1/2 trial for BMN-701, a fusion protein of insulin-like growth factor 2 and acid alpha-glucosidase (IGF2-GAA) for the treatment of late-onset Pompe disease.
View more BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development analysis
Sign-up for BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development investment picks
2013/4/9
Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting
TKM-PLK1 Resulted in Clinical Benefit in 44% of Evaluable Patients Receiving Doses in Effective Range VANCOUVER, B.C., April 9, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced the results of its Phase I clinical trial with TKM-PLK1, an RNAi therapeutic for the treatment of solid tumors.
View more Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting analysis
Sign-up for Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting investment picks
2013/5/21
Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
- Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs.
View more Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain analysis
Sign-up for Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain investment picks
2013/6/5
BioMarin Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU
SAN RAFAEL, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant Phenylalanine Ammonia Lyase) for the treatment of phenylketonuria (PKU). "In the Phase 2 trial, PEG-PAL was shown to dramatically reduce blood Phe levels, and we are hopeful that we will achieve the same outcome with the Phase 3 program," stated Hank Fuchs, M.D., Chief Medical Officer of BioMarin.
View more BioMarin Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU analysis
Sign-up for BioMarin Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU investment picks
2013/2/6
Derma Sciences Initiates Enrollment in DSC127 Phase 3 Trial for Healing Diabetic Foot Ulcers
Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announces that enrollment of patients has commenced in the first of two Phase 3 clinical trials with the Company’s investigational topical drug candidate DSC127.
View more Derma Sciences Initiates Enrollment in DSC127 Phase 3 Trial for Healing Diabetic Foot Ulcers analysis
Sign-up for Derma Sciences Initiates Enrollment in DSC127 Phase 3 Trial for Healing Diabetic Foot Ulcers investment picks
2013/2/13
Pembina Pipeline Corporation Announces Moving Forward with $250 Million Phase 2 Crude Oil and Condensate Pipeline Expansion
Pembina Pipeline Corporation Announces Moving Forward with $250 Million Phase 2 Crude Oil and Condensate Pipeline Expansion Canada NewsWire Pembina has secured required contracts to underpin 55,000 barrel per day capacity expansion to its Peace Pipeline CALGARY , Feb.
View more Pembina Pipeline Corporation Announces Moving Forward with $250 Million Phase 2 Crude Oil and Condensate Pipeline Expansion analysis
Sign-up for Pembina Pipeline Corporation Announces Moving Forward with $250 Million Phase 2 Crude Oil and Condensate Pipeline Expansion investment picks
2013/4/23
CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under a special protocol assessment (SPA) for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.
View more CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma analysis
Sign-up for CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma investment picks
2013/5/6
Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
-Targets difficult-to-treat patient population with few remaining options - - MEK162 also expected to advance into Phase 3 studies in NRAS and BRAF melanoma in 2013- BOULDER, Colo.
View more Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer analysis
Sign-up for Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer investment picks
2013/5/6
CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma
CytRx Corporation (NASDAQ:CYTR) , a biopharmaceutical research and development company specializing in oncology, announced that the independent Data Safety Monitoring Committee (DSMC) overseeing the Company’s international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma has recommended conducting the clinical trial through completion.
View more CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma analysis
Sign-up for CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma investment picks
2013/6/3
CytRx Announces the Presentation of Favorable Results from Novel Combination of Aldoxorubicin and Doxorubicin in a Phase 1b Clinical Trial at ASCO Conference
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, announced that preliminary results from a Phase 1b clinical trial determined that aldoxorubicin, the Company’s improved version of the widely used chemotherapeutic agent doxorubicin, administered at 90% of its single agent dose can be safely delivered in combination with doxorubicin administered at 50% of its single agent dose to patients with advanced solid tumors.
View more CytRx Announces the Presentation of Favorable Results from Novel Combination of Aldoxorubicin and Doxorubicin in a Phase 1b Clinical Trial at ASCO Conference analysis
Sign-up for CytRx Announces the Presentation of Favorable Results from Novel Combination of Aldoxorubicin and Doxorubicin in a Phase 1b Clinical Trial at ASCO Conference investment picks
2013/6/3
Clovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I/II Study in EGFR-mutant Non-Small Cell Lung Cancer
Clovis Oncology (NASDAQ:CLVS) today announced initial findings from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M.
View more Clovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I/II Study in EGFR-mutant Non-Small Cell Lung Cancer analysis
Sign-up for Clovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I/II Study in EGFR-mutant Non-Small Cell Lung Cancer investment picks
2013/6/2
ARIAD Presents Updated Phase 1 Data on AP26113 in Patients with Non-Small Cell Lung Cancer
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113 , in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.
View more ARIAD Presents Updated Phase 1 Data on AP26113 in Patients with Non-Small Cell Lung Cancer analysis
Sign-up for ARIAD Presents Updated Phase 1 Data on AP26113 in Patients with Non-Small Cell Lung Cancer investment picks
2013/2/28
CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, announced that enrollment of 140 evaluable patients has been completed in the Company’s global Phase 2b clinical trial with its oral retinoid compound tamibarotene in combination with chemotherapeutic agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). “Tamibarotene could represent a multi-billion dollar market opportunity as a breakthrough in the treatment of NSCLC,” said CytRx CEO Steven A.
View more CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer analysis
Sign-up for CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer investment picks
2013/2/13
Pembina Pipeline Corporation Announces Moving Forward with $250 Million Phase 2 Crude Oil and Condensate Pipeline Expansion
Pembina has secured required contracts to underpin 55,000 barrel per day capacity expansion to its Peace Pipeline CALGARY , Feb.
View more Pembina Pipeline Corporation Announces Moving Forward with $250 Million Phase 2 Crude Oil and Condensate Pipeline Expansion analysis
Sign-up for Pembina Pipeline Corporation Announces Moving Forward with $250 Million Phase 2 Crude Oil and Condensate Pipeline Expansion investment picks
2013/1/29
New Adaptive Phase 3 Trial Planned for GencaroTM in Atrial Fibrillation
ARCA biopharma, Inc. (Nasdaq: ABIO) , a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today provided an update on a proposed, genetically-targeted clinical trial in atrial fibrillation (“AF”) of the Company’s lead developmental drug, Gencaro (bucindolol hydrochloride). The Company also announced that Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, has signed a non-binding Letter of Intent to collaborate on the initial, Phase 2B portion of the proposed trial.
View more New Adaptive Phase 3 Trial Planned for GencaroTM in Atrial Fibrillation analysis
Sign-up for New Adaptive Phase 3 Trial Planned for GencaroTM in Atrial Fibrillation investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Research Phase
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Articles by:
Title |  Date |  Author |  Collection |  Interest |  Popularity
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Permit  |  Next: Research Pipeline
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.